Please try another search
For the three months ended 28 February 2022, Tetra Bio Pharma Inc revenues was not reported. Net loss decreased 81% to C$1.6M. Lower net loss reflects Research and development decrease of 61% to C$1.6M (expense), Office, Insurance and Miscellaneous decrease of 88% to C$206K (expense), Professional fees decrease of 60% to C$535K (expense).
Period Ending: | Feb 28, 2022 | Nov 30, 2021 | Aug 31, 2021 | May 31, 2021 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -3.73 | -29.39 | -5.86 | -7 |
Net Income | -1.63 | -30.19 | -5.77 | -7.86 |
Period Ending: | Feb 28, 2022 | Nov 30, 2021 | Aug 31, 2021 | May 31, 2021 |
---|---|---|---|---|
Total Assets | 8.8 | 7.55 | 36.99 | 44.02 |
Total Liabilities | 8.27 | 7.3 | 6.37 | 8.22 |
Total Equity | 0.53 | 0.25 | 30.62 | 35.8 |
Period Ending: | Feb 28, 2022 | Nov 30, 2021 | Aug 31, 2021 | May 31, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -2.39 | -25.28 | -22.27 | -14.72 |
Cash From Investing Activities | 0 | -2.12 | -1.44 | -1.3 |
Cash From Financing Activities | 1.18 | 29.78 | 29.78 | 29.75 |
Net Change in Cash | -1.21 | 2.39 | 6.07 | 13.74 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review